| Author, Year  Trial Name  N | Drug, Dose X Duration (N) | Active TB Disease,  N (%) | Transmission, N (%) | Quality of Life | Overall Mortality,  N (%) | Disease-Specific Mortality,  N (%) |
| --- | --- | --- | --- | --- | --- | --- |
| Bush, 196543  All subjects:  2,238  ≥15 years: 1,309  ≥20 years: 1,140 | INH 250 mg/day x 12 months (569).  Placebo (571). | All subjects (adults and children):  8 (0.73)a  11 (0.96)b  Subjects ≥15 years:  4 (0.60)  7 (1.08) | NR | NR | NR  NR | NR  NR |
| Falk, 197841,148  7,036 | INH 300 mg daily x 2 years (2166).  INH 300 mg daily x 1 year, followed by placebo x 1 year (2,553).  Placebo daily x 2 years (2,317). | 17 (0.8)  20 (0.8)  26 (1.1)  Among those with no prior treatment for TB (2,389 subjects):  8  5  15  Reactivators who had received previous treatment:  9 (0.6)  15 (0.9)  11 (0.7)  Reactivators who had received previous adequatec treatment  5  13  5d | NR | NR | Total deaths: 357  Rate:  4/1,000  6.5/1,000  4.4/1,000  p=0.0001 for INH 1 year vs. placebo; NR for other comparisons | 2 (0.03) deaths from TB (both received INH; 1 occurred at the 6th month of INH therapy and 1 in a patient who completed only 2 months of INH and died 11 months later) |
| Ferebee, 196344  27,924 patients (566 psychiatric wards randomized); 25,210 patients included in morbidity analyses | INH 4-7 mg/kg/day (average of 5 mg/kg) x 12 months (14,407 in randomized sample; 12,884 analyzed).  Placebo x 12 months (13,517; 12,326). | Cases diagnosed during first 15 months of the trial:  Total  4 (0.03)  21 (0.17)  Among those with abnormal CXR  3 (0.25)  14 (1.31)  Among those who were tuberculin positive  0 (0.0)  7 (0.11)  Tuberculin negative  0 (0.0)  0 (0.0)  Unknown tuberculin status  1 (0.11)  0 (0.0)  Cases developing after medication year  Total  15 (0.12)  30 (0.24)  Among those with abnormal CXR  5 (0.41)  9 (0.84)  Among those who were tuberculin positive  5 (0.08)  17 (0.26)  Cases appearing by May 1962 in subjects age ≥20 years in placebo group  Males <150 lbs: 21 (1.14)  Males ≥150 lbs: 3 (0.20)  Females <130 lbs: 8 (0.46)  Females ≥130 lbs: 2 (0.10)  Cases based on TB infection status in placebo group:  Initial tuberculin reactions <5 mm: 4 (0.10)  Initial tuberculin ≥5 mm: 24 (0.37)  Abnormal roentgenogram: 23 (2.15) | NR | NR | During treatment year, among the full randomized samplee:  752 (5.2)  611 (4.5)  Among patients who took only 1 medication (excluding crossovers):  695 (5.4%)  547 (4.4%) | NR |
| Veening, 196842  261 | INH 600 mg (8-10 mg/kg) x 4 months, then 400 mg (5-7 mg/kg) until 1 year (133).  Placebo (128). | 1 year:  1 (0.8)  9 (7.0)  4 years:  1 (0.8)  12 (9.4)  7 years:  1 (0.8)  12 (9.4) | NR | NR | NR | NR |

a No cases first 3 months after starting treatment; 1 case between months 6 and 11; 7 cases 11 months or more after starting treatment. Days index case in home by new cases: 1-60 days: 2; 61-180 days: 4; 181-270 days: 1; 270-300 days: 1.

b No cases first 3 months after starting treatment; 2 cases between months 6 and 11; 9 cases 11 months or more after starting treatment. Days index case in home by new cases: 1-60 days: 2; 61-180 days: 2; 181-270 days: 5; 270-300 days: 2.

c Adequate treatment was defined as at least 18 months of therapy with two drugs.

d Rate of reactivation was 7.3/1,000 for those with adequate prior chemotherapy and 12.7/1,000 for those with inadequate or no prior chemotherapy.

e Deaths in wards participating in the trial during the year prior to the trial: INH 801 (5.6), placebo 698 (5.2). Change in percent of deaths from year prior to the trial to the medication year: INH -0.4%; placebo -0.7%.

**Abbreviations:** CXR=chest x-ray; INH=isoniazid; N=sample size; NR=not reported; TB=tuberculosis.